Intellia Therapeutics, Inc.
NTLANext catalyst
NTLA-2002
hereditary angioedema (“HAE”)
Get an email about NTLA's next catalysts
Track Intellia Therapeutics (NTLA) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 4 more upcoming events in our data (regulatory event, PDUFA date, Phase 3 readout).See the timeline
5 upcoming, 1 past
Regulatory — Intellia gene editor
For hereditary angioedema. Intellia Therapeutics' gene editing therapy for hereditary angioedema is positioned as a potential paradigm-shifter with a one-time dosing profile, with market approval anticipated in 2027. Jefferies notes the asset could keep pace with Ionis' competing treatment in this indication.
SourceFDA PDUFA Date (priority review)
BLA filing. Extracted from: Intellia Therapeutics Announces Third Quarter 2026 Financial Results
SourceFDA PDUFA Date NTLA-2002 (priority)
For hereditary angioedema (“HAE”). bla filing. Extracted from SEC filing: EX-99.1
SourcePhase 3 — lonvo-z
Intellia announced positive Phase III data for lonvo-z, supporting continuation of its rolling BLA submission with expected completion by year-end 2026 and FDA approval targeted for the first half of 2027.
Sourcenexiguran ziclumeran Phase 3 Est. Readout
Primary completion for nexiguran ziclumeran trial (NCT06672237) in Neuromuscular Disease
SourceUpcoming FDA decisions
Market Overview
Stock performance and key metrics
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.
WebsiteNTLA-2002
Hereditary Angioedema
NTLA-2001
Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
nexiguran ziclumeran
Neuromuscular Disease
Biological NTLA-2002
Hereditary Angioedema
LNP1265
Hemophilia B
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
NTLA-2002 | Phase 3 | Hereditary Angioedema | - | - |
NTLA-2001 | Phase 3 | Transthyretin Amyloidosis (ATTR) With Cardiomyopathy | - | - |
nexiguran ziclumeran | Phase 3 | Neuromuscular Disease | - | - |
Biological NTLA-2002 | Phase 2 | Hereditary Angioedema | - | - |
LNP1265 | Phase 2 | Hemophilia B | - | - |
Frequently asked questions
What is in Intellia Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 5 drug candidates in Intellia Therapeutics, Inc.'s (NTLA) pipeline across Phase 3, Phase 2. Its lead program is NTLA-2002 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Intellia Therapeutics, Inc.'s next FDA catalyst?→
Intellia Therapeutics, Inc.'s (NTLA) next tracked catalyst is a PDUFA date expected Mar 10, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track NTLA biotech catalysts?→
Add NTLA to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Intellia Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.